Alcon: launches new lens for US cataract patients
(CercleFinance.com) - Alcon has commercially launched a new presbyopia-mitigating lens in the US, aiming to help ophthalmologists treat patients undergoing cataract surgery.
The move comes as the US market is expected to grow to 5.4 million cataract surgeries by 2025, doubling by 2050, due to the aging population, the Swiss eye care expert said.
Cataracts are the most common cause of vision loss.
The intraocular lens, called "Vivity," received FDA approval in early 2020, and it was made available to some US ophthalmologists during a pilot phase, ahead of the current launch.
It is already available in some European markets, Australia, New Zealand, Canada and Latin America.
Copyright (c) 2021 CercleFinance.com. All rights reserved.